Porton Pharma Solutions Ltd. (300363.SZ)
CNY 17.08
(0.59%)
CNY 17.08
(0.59%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.16 Billion CNY | -23.99% |
| 2022 | 1.36 Billion CNY | 111.66% |
| 2021 | 646.68 Million CNY | 42.6% |
| 2020 | 453.5 Million CNY | 24.79% |
| 2019 | 363.42 Million CNY | 37.57% |
| 2018 | 264.18 Million CNY | 7.41% |
| 2017 | 245.96 Million CNY | -6.37% |
| 2016 | 262.68 Million CNY | 43.42% |
| 2015 | 183.16 Million CNY | -1.51% |
| 2014 | 185.96 Million CNY | 22.22% |
| 2013 | 152.15 Million CNY | 26.65% |
| 2012 | 120.13 Million CNY | 19.73% |
| 2011 | 100.34 Million CNY | 45.16% |
| 2010 | 69.12 Million CNY | 28.13% |
| 2009 | 53.94 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 217.78 Million CNY | -9.38% |
| 2024 Q3 | 235.78 Million CNY | 32.76% |
| 2024 Q1 | 240.32 Million CNY | 10.12% |
| 2023 Q4 | 218.24 Million CNY | -16.89% |
| 2023 Q1 | 363.51 Million CNY | -1.54% |
| 2023 Q3 | 262.61 Million CNY | -26.58% |
| 2023 Q2 | 357.68 Million CNY | -1.6% |
| 2023 FY | 1.04 Billion CNY | -23.99% |
| 2022 Q2 | 350.56 Million CNY | 35.79% |
| 2022 FY | 1.36 Billion CNY | 111.66% |
| 2022 Q4 | 369.21 Million CNY | -5.54% |
| 2022 Q3 | 390.85 Million CNY | 11.49% |
| 2022 Q1 | 258.16 Million CNY | 60.08% |
| 2021 FY | 646.68 Million CNY | 42.6% |
| 2021 Q1 | 136.74 Million CNY | 7.72% |
| 2021 Q4 | 161.27 Million CNY | -11.56% |
| 2021 Q3 | 182.36 Million CNY | 9.67% |
| 2021 Q2 | 166.29 Million CNY | 21.6% |
| 2020 FY | 453.5 Million CNY | 24.79% |
| 2020 Q4 | 126.95 Million CNY | 4.88% |
| 2020 Q3 | 121.03 Million CNY | 16.56% |
| 2020 Q2 | 103.84 Million CNY | 2.14% |
| 2020 Q1 | 101.66 Million CNY | -12.98% |
| 2019 Q3 | 91.94 Million CNY | -2.06% |
| 2019 Q4 | 116.83 Million CNY | 27.07% |
| 2019 FY | 363.42 Million CNY | 37.57% |
| 2019 Q1 | 60.76 Million CNY | -6.54% |
| 2019 Q2 | 93.87 Million CNY | 54.5% |
| 2018 Q2 | 73.54 Million CNY | 31.44% |
| 2018 FY | 264.18 Million CNY | 7.41% |
| 2018 Q4 | 65.01 Million CNY | -6.69% |
| 2018 Q3 | 69.67 Million CNY | -5.26% |
| 2018 Q1 | 55.95 Million CNY | 17.07% |
| 2017 Q1 | 59.19 Million CNY | -38.06% |
| 2017 FY | 245.96 Million CNY | -6.37% |
| 2017 Q4 | 47.79 Million CNY | -32.62% |
| 2017 Q3 | 70.92 Million CNY | 4.24% |
| 2017 Q2 | 68.04 Million CNY | 14.94% |
| 2016 Q3 | 52.78 Million CNY | -21.23% |
| 2016 Q2 | 67.01 Million CNY | 41.65% |
| 2016 Q4 | 95.57 Million CNY | 81.05% |
| 2016 FY | 262.68 Million CNY | 43.42% |
| 2016 Q1 | 47.3 Million CNY | -12.6% |
| 2015 FY | 183.16 Million CNY | -1.51% |
| 2015 Q4 | 54.12 Million CNY | 22.96% |
| 2015 Q3 | 44.02 Million CNY | 15.0% |
| 2015 Q2 | 38.27 Million CNY | -18.09% |
| 2015 Q1 | 46.73 Million CNY | -29.92% |
| 2014 Q2 | 38.32 Million CNY | 2.87% |
| 2014 Q1 | 37.24 Million CNY | -27.61% |
| 2014 FY | 185.96 Million CNY | 22.22% |
| 2014 Q4 | 66.67 Million CNY | 52.52% |
| 2014 Q3 | 43.71 Million CNY | 14.09% |
| 2013 Q2 | 32.51 Million CNY | 1.9% |
| 2013 FY | 152.15 Million CNY | 26.65% |
| 2013 Q1 | 31.9 Million CNY | 0.0% |
| 2013 Q3 | 36.27 Million CNY | 11.59% |
| 2013 Q4 | 51.46 Million CNY | 41.84% |
| 2012 FY | 120.13 Million CNY | 19.73% |
| 2011 FY | 100.34 Million CNY | 45.16% |
| 2010 FY | 69.12 Million CNY | 28.13% |
| 2009 FY | 53.94 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Beijing Scitop Bio-tech Co., Ltd. | 84.97 Million CNY | -1274.785% |
| Lifecome Biochemistry Co.,Ltd. | 190.7 Million CNY | -512.574% |
| Chengdu Kanghua Biological Products Co., Ltd. | 898.63 Million CNY | -29.998% |
| NanHua Bio-medicine Co., Ltd | 137.65 Million CNY | -748.623% |
| Shandong Sito Bio-technology Co., Ltd. | 235.57 Million CNY | -395.899% |
| Zhejiang Wecome Pharmaceutical Company Limited | 262.87 Million CNY | -344.404% |
| Guangdong VTR Bio-Tech Co., Ltd. | 331.11 Million CNY | -252.809% |